Investigations into the emergence of pertactin-deficient bordetella pertussis isolates in six European countries, 1996 to 2012

Eurosurveillance

Volumn 19, Issue 33, 2014, Pages

  Zeddeman, A ^a   van Gent, M ^a   Heuvelman, C J ^a   van der Heide, H G ^a   Bart, M J ^a   Advani, A ^b   Hallander, H O ^b   Wirsing von Konig C H ^c   Riffelman, M ^c   Storsaeter, J ^d   Vestrheim, D F ^d   Dalby, T ^e   Krogfelt, K A ^e   Fry, N K ^f   Barkoff, A M ^g   Mertsola, J ^h   He, Q ^g   Mooi, F ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^c Klinikum Krefeld   (Germany)

^d NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^e STATENS SERUM INSTITUT   (Denmark)

^f PUBLIC HEALTH ENGLAND   (United Kingdom)

^g NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^h TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

PERTACTIN; PERTUSSIS TOXIN; PERTUSSIS VACCINE;

ADOLESCENT; AGED; ANTIGEN EXPRESSION; ARTICLE; BACTERIUM ISOLATE; BORDETELLA PERTUSSIS; CAPILLARY ELECTROPHORESIS; CHILD; CONTROLLED STUDY; DISEASE RE-EMERGENCE; DNA ISOLATION; DNA SEQUENCE; EPIDEMIOLOGICAL DATA; EUROPE; HUMAN; IMMUNOBLOTTING; INFANT; MULTILOCUS SEQUENCE TYPING; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; PERTUSSIS; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PROMOTER REGION; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; VACCINATION;

EID: 84906724905     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/1560-7917.ES2014.19.33.20881     Document Type: Article

References (45)

1. Berbers GA, de Greef SC, Mooi FR., Improving pertussis vaccination. Hum Vaccin. 2009;5(7):497-503. http://dx.doi.org/10.4161/hv.8112
2. He Q, Mertsola J. Factors contributing to pertussis resurgence. Future Microbiol. 2008;3(3):329-39. http://dx.doi.org/10.2217/17460913.3.3.329
3. Mooi FR. Bordetella pertussis and vaccination: the persistence of a genetically monomorphic pathogen. Infect Genet Evol. 2010;10(1):36-49. http://dx.doi.org/10.1016/j.meegid.2009.10.007
4. Conyn van Spaendock MA, Van der Maas NA, Mooi FR.Control of whooping cough in the Netherlands: optimisation of the vaccination policy. Bilthoven: National Institute for Public Health and the Environment (RIVM); 2012. RIVM report 215121002. Synposis available from: http://www.rivm.nl/en/Documents_and_publications/Scientific/Reports/2013/februari/Control_of_whoopin g_cough_in_the_Netherlands_Optimisation_of_the_vaccination_policy
5. Public Health England (PHE). Confirmed pertussis in England and Wales: data to end-December 2012. Health Protection Report. 2013;7(5). Available from: http://www.hpa.org.uk/hpr/archives/2013/news0513.htm
6. Schmidtke AJ. Boney KO, Martin SW, Skoff TH, Tondella ML, Tatti KM. Population diversity among Bordetella pertussis isolates, United States, 1935-2009. Emerg Infect Dis. 2012;18(8):1248-55. http://dx.doi.org/10.3201/eid1808.120082
7. Mooi FR, Van Der Maas NA, De Melker HE. Pertussis resurgence: waning immunity and pathogen adaptation - two sides of the same coin. Epidemiol Infect. 2014;142(4):685-94. http://dx.doi.org/10.1017/S0950268813000071
8. Ntezayabo B, De Serres G, Duval B. Pertussis resurgence in Canada largely caused by a cohort effect. Pediatr Infect Dis J. 2003;22(1):22-7. http://dx.doi.org/10.1097/00006454-200301000-00009
9. Tartof SY, Lewis M, Kenyon C, White K, Osborn A, Liko J, et al., Waning immunity to pertussis following 5 doses of DTaP. Pediatrics. 2013;131(4):e1047-52. http://dx.doi.org/10.1542/peds.2012-1928
10. Liko J, Robison SG, Cieslak PR. Priming with whole-cell versus acellular pertussis vaccine. N Engl J Med. 2013;368(6):581-2. http://dx.doi.org/10.1056/NEJMc1212006
11. Sheridan SL, Ware RS, Grimwood K, Lambert SB. Number and order of whole cell pertussis vaccines in infancy and disease protection. JAMA. 2012;308(5):454-6. http://dx.doi.org/10.1001/jama.2012.6364
12. Hallander HO, Andersson M, Gustafsson L, Ljungman M, Netterlid E. Seroprevalence of pertussis antitoxin (anti-PT) in Sweden before and 10 years after the introduction of a universal childhood pertussis vaccination program. APMIS. 2009;117(12):912-22. http://dx.doi.org/10.1111/j.1600-0463.2009.02554.x
13. Lam C, Octavia S, Bahrame Z, Sintchenko V, Gilbert GL, Lan R. Selection and emergence of pertussis toxin promoter ptxP3 allele in the evolution of Bordetella pertussis. Infect Genet Evol. 2012;12(2):492-5. http://dx.doi.org/10.1016/j.meegid.2012.01.001
14. van Gent M, Bart MJ, van der Heide HG, Heuvelman KJ, Mooi FR. Small mutations in Bordetella pertussis are associated with selective sweeps. PLoS One. 2012;7(9): e46407. http://dx.doi.org/10.1371/journal.pone.0046407
15. Fry NK, Neal S, Harrison TG, Miller E, Matthews R, George RC. Genotypic variation in the Bordetella pertussis virulence factors pertactin and pertussis toxin in historical and recent clinical isolates in the United Kingdom. Infect Immun. 2001;69(9):5520-8. http://dx.doi.org/10.1128/IAI.69.9.5520-5528.2001
16. Mooi FR, van Loo IH, van Gent M, He Q, Bart MJ, Heuvelman KJ, et al. Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. Emerg Infect Dis. 2009;15(8):1206-13. http://dx.doi.org/10.3201/eid1508.081511
17. Bouchez V, Brun D, Cantinelli T, Dore G, Njamkepo E, Guiso N. First report and detailed characterization of B. pertussis isolates not expressing pertussis toxin or pertactin. Vaccine. 2009;27(43):6034-41. http://dx.doi.org/10.1016/j.vaccine.2009.07.074
18. Otsuka N, Han HJ, Toyoizumi-Ajisaka H, Nakamura Y, Arakawa Y, Shibayama K, et al. Prevalence and genetic characterization of pertactin-deficient Bordetella pertussis in Japan. PLoS One. 2012;7(2): e31985. http://dx.doi.org/10.1371/journal.pone.0031985
19. Hegerle N, Paris AS, Brun D, Dore G, Njamkepo E, Guillot S, et al. Evolution of French Bordetella pertussis and Bordetella parapertussis isolates: increase of Bordetellae not expressing pertactin. Clin Microbiol Infect. 2012;18(9):E340-6. http://dx.doi.org/10.1111/j.1469-0691.2012.03925.x
20. Barkoff AM, Mertsola J, Guillot S, Guiso N, Berbers G, He Q. Appearance of Bordetella pertussis strains not expressing the vaccine antigen pertactin in Finland. Clin Vaccine Immunol. 2012;19(10):1703-4. http://dx.doi.org/10.1128/CVI.00367-12
21. Queenan AM, Cassiday PK, Evangelista A. Pertactin-negative variants of Bordetella pertussis in the United States. N Engl J Med.. 2013;368(6):583-4. http://dx.doi.org/10.1056/NEJMc1209369
22. Pawloski LC, Queenan AM, Cassiday PK, Lynch AS, Harrison MJ, Shang W, et al. Prevalence and molecular characterization of pertactin-deficient Bordetella pertussis in the United States. Clin Vaccine Immunol. 2014;21(2):119-25. http://dx.doi.org/10.1128/CVI.00717-13
23. Advani A, Gustafsson L, Ahrén C, Mooi FR, Hallander HO. Appearance of Fim3 and ptxP3-Bordetella pertussis strains, in two regions of Sweden with different vaccination programs. Vaccine. 2011;29(18):3438-42. http://dx.doi.org/10.1016/j.vaccine.2011.02.070
24. Kallonen T, Mertsola J, Mooi FR, He Q. Rapid detection of the recently emerged Bordetella pertussis strains with the ptxP3 pertussis toxin promoter allele by real-time PCR. Clin Microbiol Infect. 2012;18(10):E377-9. http://dx.doi.org/10.1111/j.1469-0691.2012.04000.x
25. Petersen RF, Dalby T, Dragsted DM, Mooi F, Lambertsen L. Temporal trends in Bordetella pertussis populations, Denmark, 1949-2010. Emerg Infect Dis. 2012;18(5):767-74. http://dx.doi.org/10.3201/eid1805.110812
26. Shuel M, Jamieson FB, Tang P, Brown S, Farrell D, Martin I, et al. Genetic analysis of Bordetella pertussis in Ontario, Canada reveals one predominant clone. Int J Infect Dis. 2013;17(6):e413-7. http://dx.doi.org/10.1016/j.ijid.2012.12.015
27. King AJ, van der Lee S, Mohangoo A, van Gent M, van der Ark A, van de Waterbeemd B. Genome-wide gene expression analysis of Bordetella pertussis isolates associated with a resurgence in pertussis: elucidation of factors involved in the increased fitness of epidemic strains. PLoS One. 2013;8(6):e66150. http://dx.doi.org/10.1371/journal.pone.0066150
28. Guiso N. Bordetella pertussis and pertussis vaccines. Clin Infect Dis. 2009;49(10):1565-9. http://dx.doi.org/10.1086/644733
29. Bodilis H, Guiso N. Virulence of pertactin-negative Bordetella pertussis isolates from infants, France. Emerg Infect Dis. 2013;19(3):471-4. http://dx.doi.org/10.3201/eid1903.121475
30. van Loo IH, Heuvelman KJ, King AJ, Mooi FR. Multilocus sequence typing of Bordetella pertussis based on surface protein genes. J Clin Microbiol. 2002;40(6):1994-2001. http://dx.doi.org/10.1128/JCM.40.6.1994-2001.2002
31. van Gageldonk PG, van Schaijk FG, van der Klis FR, Berbers GA. Development and validation of a multiplex immunoassay for the simultaneous determination of serum antibodies to Bordetella pertussis, diphtheria and tetanus. J Immunol Methods. 2008;335(1-2):79-89. http://dx.doi.org/10.1016/j.jim.2008.02.018
32. van Gent M, van Loo IH, Heuvelman KJ,de Neeling AJ,Teunis P,Mooi FR,. Studies on Prn variation in the mouse model and comparison with epidemiological data. PLoS One. 2011;6(3):e18014. http://dx.doi.org/10.1371/journal.pone.0018014
33. Nicosia A, Perugini M, Franzini C, Casagli MC, Borri MG, Antoni G, et al. Cloning and sequencing of the pertussis toxin genes: operon structure and gene duplication. Proc Natl Acad Sci U S A. 1986;83(13):4631-5. http://dx.doi.org/10.1073/pnas.83.13.4631
34. Hijnen M, Mooi FR, van Gageldonk PG, Hoogerhout P, King AJ, Berbers GA. Epitope structure of the Bordetella pertussis protein P.69 pertactin, a major vaccine component and protective antigen. Infect Immun. 2004;72(7):3716-23. http://dx.doi.org/10.1128/IAI.72.7.3716-3723.2004
35. van Gent M, Bart MJ, van der Heide HG, Heuvelman KJ, Kallonen T, He Q, et al. SNP-based typing: a useful tool to study Bordetella pertussis populations. PLoS One. 2011;6(5):e20340. http://dx.doi.org/10.1371/journal.pone.0020340
36. Octavia S, Sintchenko V, Gilbert GL, Lawrence A, Keil AD, Hogg G, et al. Newly emerging clones of Bordetella pertussis carrying prn2 and ptxP3 alleles implicated in Australian pertussis epidemic in 2008-2010. J Infect Dis. 2012;205(8):1220-4. http://dx.doi.org/10.1093/infdis/jis178
37. Weber C, Boursaux-Eude C, Coralie G., Caro V., Guiso N. Polymorphism of Bordetella pertussis isolates circulating for the last 10 years in France, where a single effective whole-cell vaccine has been used for more than 30 years. J Clin Microbiol. 2001;39(12):4396-4403. http://dx.doi.org/10.1128/JCM.39.12.4396-4403.2001
38. Greco D, Salmaso S, Mastrantonio P, Giuliano M, Tozzi AE, Anemona A, et al. A controlled trial of two acellular vaccines and one whol cell vaccine against pertussis. N Engl J Med. 1996;334(6):341-8. http://dx.doi.org/10.1056/NEJM199602083340601
39. Andersen PH, Knudsen LK, Valentiner-Branth P. DTAP-IPV/HIB vaccination coverage 2011. Copenhagen: Statens Serum Institut; 2012. EPI-news. No 23a. Available from: http://www.ssi.dk/English/News/EPI-NEWS/2012/No%2023a%20-%202012.aspx
40. van Amersfoorth SC, Schouls LM, van der Heide HG, Advani A, Hallander HO, Bondeson K, et al. Analysis of Bordetella pertussis populations in European countries with different vaccination policies. J Clin Microbiol. 2005;43(6):2837-43. http://dx.doi.org/10.1128/JCM.43.6.2837-2843.2005
41. Lavine JS, Bjørnstad ON, de Blasio BF, Storsaeter J. Short-lived immunity against pertussis, age-specific routes of transmission, and the utility of a teenage booster vaccine. Vaccine. 2012;30(3):544-51. http://dx.doi.org/10.1016/j.vaccine.2011.11.065
42. Advani A, Hallander HO, Dalby T, Krogfelt KA, Guiso N, Njamkepo E, et al. Pulsed-field gel electrophoresis analysis of Bordetella pertussis isolates circulating in Europe from 1998 to 2009. J Clin Microbiol. 2013;51(2):422-8. http://dx.doi.org/10.1128/JCM.02036-12
43. Campbell H, Amirthalingam G, Andrews N, Fry NK, George RC, Harrison TG, Miller E. Accelerating control of pertussis in England and Wales. Emerg Infect Dis. 2012;18(1):38-47. http://dx.doi.org/10.3201/eid1801.110784
44. Diavatopoulos DA, Cummings CA, Schouls LM, Brinig MM, Relman DA, Mooi FR. Bordetella pertussis, the causative agent of whooping cough, evolved from a distinct, human-associated lineage of B.bronchiseptica. PLoS Pathog. 2005;1(4):e45.
45. Mooi FR, van Oirschot H, Heuvelman K, van der Heide HG, Gaastra W, Willems RJ. Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in The Netherlands: temporal trends and evidence for vaccine-driven evolution. Infect Immun. 1998;66(2):670-5.